1. Home
  2. Uncategorized
  3. FDA approves new nasal spray for treatment-resistant depression
Uncategorized
nasal spray medication for treatment-resistant depression

FDA approves new nasal spray for treatment-resistant depression

On March 5, the FDA approved Spravato (esketamine) nasal spray, in conjunction with an oral antidepressant, for treatment-resistant depression, but it’s only available through a restricted distribution system.

Read more via U.S. Food and Drug Administration.

Leave a Reply

Your email address will not be published. Required fields are marked *

Fill out this field
Fill out this field
Please enter a valid email address.

cheryl meeGet your free access to the exclusive newsletter of American Nurse Journal and gain insights for your nursing practice.

NurseLine Newsletter

  • Hidden

*By submitting your e-mail, you are opting in to receiving information from Healthcom Media and Affiliates. The details, including your email address/mobile number, may be used to keep you informed about future products and services.

Poll

Recent Posts